What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ...
"Random skin biopsies are utilized when there is a sufficiently high concern of the diagnosis in the patient and they do not have overt clinical findings suggestive of the diagnosis. In those cases, ...
Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments. The U.S. Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . With new developments in the treatment of follicular lymphoma, such as chimeric antigen receptor T-cell ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback